Paper · 42806387
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 34
Download this page as JSON| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,296,177 | Optimizing the safety of antibody-drug conjugates for patients with solid tumours. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/37296177 | PubMed |
| 2 | 35,614,462 | Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. | J Nanobiotechnology | 2022 | https://conductscience.org/library/papers/35614462 | PubMed |
| 3 | 40,947,843 | Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study. | Future Oncol | 2025 | https://conductscience.org/library/papers/40947843 | PubMed |
| 4 | 40,217,078 | Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40217078 | PubMed |
| 5 | 35,785,754 | Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. | Cancer Treat Rev | 2022 | https://conductscience.org/library/papers/35785754 | PubMed |
| 6 | 35,320,644 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35320644 | PubMed |
| 7 | 33,552,868 | Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. | Adv Sci (Weinh) | 2021 | https://conductscience.org/library/papers/33552868 | PubMed |
| 8 | 34,664,433 | An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. | Adv Sci (Weinh) | 2021 | https://conductscience.org/library/papers/34664433 | PubMed |
| 9 | 36,620,535 | Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. | Front Oncol | 2022 | https://conductscience.org/library/papers/36620535 | PubMed |
| 10 | 40,473,437 | Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. | BMJ | 2025 | https://conductscience.org/library/papers/40473437 | PubMed |
| 11 | 38,092,229 | Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). | Ann Oncol | 2024 | https://conductscience.org/library/papers/38092229 | PubMed |
| 12 | 34,675,733 | Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. | Lung Cancer (Auckl) | 2021 | https://conductscience.org/library/papers/34675733 | PubMed |
| 13 | 39,662,227 | Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. | ESMO Open | 2024 | https://conductscience.org/library/papers/39662227 | PubMed |
| 14 | 38,502,995 | Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. | Cancer Treat Rev | 2024 | https://conductscience.org/library/papers/38502995 | PubMed |
| 15 | 38,658,782 | Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. | Br J Cancer | 2024 | https://conductscience.org/library/papers/38658782 | PubMed |
| 16 | 36,038,616 | Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. | NPJ Breast Cancer | 2022 | https://conductscience.org/library/papers/36038616 | PubMed |
| 17 | 38,636,292 | The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. | ESMO Open | 2024 | https://conductscience.org/library/papers/38636292 | PubMed |
| 18 | 40,210,967 | Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. | Nat Med | 2025 | https://conductscience.org/library/papers/40210967 | PubMed |
| 19 | 35,119,908 | Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35119908 | PubMed |
| 20 | 35,511,148 | Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. | JAMA Oncol | 2022 | https://conductscience.org/library/papers/35511148 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/42806387/references